Microsoft has announced that it has begun a development program to develop a new type of chemotherapy drug that would target the cells responsible for tumors’ growth.
The drug would be a first of its kind in human medicine and is described as a “chemo cure”.
The drug could be in the pipeline for up to 20 years.
Microsoft said the development would take about two years and would involve researchers at a company called Novartis and Novarti Research.
“We’re working with a group of leading researchers and scientists from Novartigro and Novartsis to bring a chemo cure to patients,” said Microsoft Chief Operating Officer Brad Smith in a statement.
Microsoft previously said it had a “working prototype” of the drug, which it said was working on clinical trials.
The company had initially been focused on the treatment of a few specific types of tumors in people with advanced lung cancer, but the company said it was exploring more targeted treatments for a broader spectrum of malignancies.
Microsoft’s plans to develop the drug were confirmed on Monday by the Novartic Group, which owns Novartia.
“Novartic is excited to partner with Microsoft on this important development,” said Novartin President John Bresch in a release.
Novartina is also a member of the European Medicines Agency, a regulatory body that oversees drug development.
The Novartizin project was first announced in July.
Microsoft has been looking to develop drugs to treat the treatment for a range of malignant diseases including melanoma and skin cancer.
But this is the first time that a cancer treatment has been targeted to target cells involved in the growth of tumors.
It has been unclear if the new drug would work on human cells or if it would be effective against other types of cells.
Microsoft had previously hinted that the new cancer drug could help with the disease of advanced melanoma, where the cells that produce melanoma-specific proteins are located.